Personalized antibiotic dosing may boost infection treatment
NCT ID NCT05914467
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether using personalized dosing (based on drug levels in the blood) for the antibiotic teicoplanin works better than standard dosing for treating bacterial infections. About 74 adults in hospital intensive care or other units will take part. The goal is to see if more patients reach the right drug level faster and have better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
RadboudUMC
Nijmegen, 6525GA, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug CTX-187 takes aim at stubborn bacterial infections
- Can smarter antibiotic choices curb superbugs in liver disease?
- New bedside test could help doctors fine-tune antibiotics in real time
- Vaccine Follow-Up: how long does protection last in babies?
- New antibiotic vabomere tested in kids for first time
- Could personalized antibiotic dosing save lives in liver cirrhosis?